DSGN
Design Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$10.64
+3.20%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-35.1%
Return on equity
-32.9%
Return on assets
-38.9%
Return on invested capital
0.00x
Asset turnover
-$55.1M
Cash from operations
$3.31
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026